Core Points - Suominen Corporation is launching a cost-saving program aimed at securing profitable growth and enhancing long-term competitiveness [1][2] - The program is expected to generate savings of approximately EUR 10 million over the next 24 months [3] - The initiative may impact up to 60 positions globally, pending local consultation procedures [3] Company Overview - Suominen manufactures nonwovens as roll goods for wipes and other applications, with a vision to lead in nonwovens innovation and sustainability [4] - In 2024, Suominen reported net sales of EUR 462.3 million and employs over 700 professionals across Europe and the Americas [4] - The company's shares are listed on Nasdaq Helsinki [4]

Suominen Corporation’s Interim Report on May 7, 2025, at 9:30 a.m. (EEST)Suominen Corporation’s Interim Report for January 1 – March 31, 2025: Navigating a challenging environment KEY FIGURES 1-3/1-3/1-12/ 202520242024Net sales, EUR million117.5113.6462.3Comparable EBITDA, EUR million4.14.517.0Comparable EBITDA, %3.53.93.7EBITDA, EUR million4.14.717.2EBITDA, %<td style="width:89.34px;;text-align ...

Montrouge, May 7, 2025 CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184)* Crédit Agricole S.A. (the “Issuer”) announces today the redemption (the “Redemption”) with effect on June 5, 2025 (the “Redemption Date”) of all of its outstanding EUR 750,000,000 Subordinated Fixed Rate Resettable Notes issued on June 5, 2020 (ISIN: FR0013516184) (the “Notes”) pursuant to Condition 6(e) (Redemption at the Option of the Iss ...

Core Viewpoint - Monopar Therapeutics Inc. is presenting promising long-term efficacy and safety data for its drug candidate ALXN1840 for Wilson disease at the EASL International Liver Congress 2025, indicating its potential as a therapeutic option for patients with this rare genetic condition [1][2][3] Group 1: Efficacy and Safety Data - The efficacy data were pooled from three clinical trials involving a total of 255 patients, while safety data were derived from an additional trial with 266 patients [2] - The median treatment duration for efficacy was 961 days (approximately 2.63 years) and for safety was 943.5 days (approximately 2.58 years) [2] - Sustained improvements were observed in the Unified Wilson Disease Rating Scale (UWDRS) for both patient-reported and clinician-assessed symptoms [6] - There was a significant increase in copper mobilization, evidenced by a sustained increase in directly measured non-ceruloplasmin-bound copper (dNCC) [6] - Improvements were noted on the Clinical Global Impression – Improvement (CGI-I) scale for ALXN1840 compared to standard care [6] - The New Wilson Index showed improvement for patients treated with ALXN1840, based on various clinical parameters [6] - Patient-reported convenience and effectiveness of ALXN1840 were higher compared to standard care, especially among those transitioning from standard care to ALXN1840 [6] - Fewer than 5% of patients experienced drug-related serious adverse events, with no cases reported for renal or urinary system issues [6] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments, including ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [4]

Company Announcement No 20/20257 May 2025 Sydbank’s Interim Report – Q1 2025 Q1 2025 – highlights Profit for the period of DKK 645m equals a return on equity of 17.4% p.a. after taxCore income of DKK 1,700m is 8% lower compared to the same period in 2024Trading income of DKK 64m compared to DKK 89m in the same period in 2024Costs (core earnings) of DKK 881m compared to DKK 831m in the same period in 2024Core earnings before impairment of DKK 883m are 20% lower compared to the same period in 2024Impairment ...

Core Insights - Arbutus Biopharma Corporation presented promising data on imdusiran and AB-101 at the EASL Congress 2025, indicating potential for functional cure in chronic hepatitis B patients [1][5] Group 1: Imdusiran and Clinical Trials - Imdusiran, when combined with VTP-300 and low-dose nivolumab, has shown to achieve functional cure in chronic hepatitis B (cHBV) patients [1] - In the Phase 2a clinical trial (IM-PROVE II), patients receiving imdusiran (60mg every 8 weeks) demonstrated significant reductions in HBsAg levels, with 25% of patients in the group receiving nivolumab achieving functional cure [2][7] - A total of 8 patients across all Phase 2a trials have been reported to achieve functional cure, with 7 of these having baseline HBsAg levels below 1000 IU/mL [3] Group 2: AB-101 and Safety Profile - AB-101, an oral PD-L1 inhibitor, has been shown to be generally safe and well-tolerated in a Phase 1a/1b clinical trial, with no liver dysfunction reported in cHBV patients [1][4] - Data from the first cohort of cHBV patients indicated that daily dosing of 10mg of AB-101 for 28 days was well tolerated, with no immune-related adverse events reported [4][10] Group 3: Background on Hepatitis B and Arbutus - Chronic hepatitis B infection represents a significant unmet medical need, affecting over 250 million people globally, with approximately 1.1 million deaths annually from related complications [11] - Arbutus Biopharma is focused on developing innovative therapies for infectious diseases, particularly chronic HBV infection, and is also involved in legal actions to protect its intellectual property [12]

Core Insights - OP Financial Group reported a strong operating profit of EUR 423 million for Q1 2025, despite a 31.4% decrease compared to the same period in 2024, reflecting challenges in the operating environment [2][13][32] - The economic outlook remains uncertain due to geopolitical tensions and trade wars, with GDP growth in Finland projected at 1% for the year [9][10][48] Financial Performance - Total income decreased by 17.1% to EUR 989 million, while total expenses increased by 10% to EUR 590 million, leading to a weakened cost/income ratio of 60% [2][17][32] - Net interest income fell by 11% to EUR 631 million, with Retail Banking experiencing a 17% decline [4][33] - The Corporate Banking segment saw an operating profit increase of 13% to EUR 145 million, while the Insurance segment reported an operating loss of EUR -14 million [18][32] Business Segments - Retail Banking's operating profit decreased by 23% to EUR 291 million, with a 4% increase in deposits to EUR 64 billion [4][18] - Corporate Banking's loan portfolio grew by 1% to EUR 28.2 billion, with deposits increasing by 14% [4][18] - The Insurance segment's service result improved to EUR 2 million, but investment income plummeted by 88% to EUR 19 million [4][16] Customer Engagement and Initiatives - OP Financial Group increased OP bonuses for owner-customers by 40% compared to 2022, providing significant value during economically challenging times [13][32] - The number of systematic investment agreements increased by 22%, indicating strong customer interest in long-term investments [22][23] Capital and Liquidity - The CET1 ratio stood at 20.0%, exceeding the minimum regulatory requirement by 6.9 percentage points, indicating strong capital adequacy [14][42] - The liquidity position remains robust, with a liquidity coverage ratio (LCR) of 202% [42] Market Trends - The loan portfolio grew by 1% year-on-year to EUR 99.1 billion, with deposits increasing by 5% to EUR 77.5 billion [19][20] - The ratio of non-performing exposures decreased to 2.5%, reflecting improved credit quality [21][34] Outlook - The operating profit for 2025 is expected to be good but lower than in 2023 and 2024, amid a challenging economic environment [48][49]

Group 1 - UAB Delfi, a subsidiary of AS Ekspress Grupp, is finalising an acquisition agreement to merge with UAB Kenton Baltic, which focuses on conference organization [1] - The restructuring aims to improve management efficiency and transparency [1] - The merger will not affect the consolidated profit, assets, or liabilities of AS Ekspress Grupp [1] Group 2 - AS Ekspress Grupp is the leading media group in the Baltic region, involved in web media content production, and publishing newspapers, magazines, and books [1] - The group also operates an electronic ticket sales platform and ticket sales offices, and provides outdoor screen services in Estonia and Latvia [1] - Established in 1989, AS Ekspress Grupp employs nearly 1,100 people [1]

Core Insights - Wolters Kluwer reported a solid start to 2025 with sustained growth in recurring revenues and margin improvement, reaffirming full-year guidance [4][8][17] Financial Performance - First-quarter revenues increased by 8% in reporting currencies, with organic growth of 5% compared to 6% in 1Q 2024 [5] - Recurring revenues, which constitute 83% of total revenues, grew by 7% organically, consistent with the previous year [5] - Non-recurring revenues declined by 2% organically, with notable growth in Financial & Corporate Compliance and Legal & Regulatory transactional revenues [5][9][10] - Adjusted operating profit increased by 11% at constant currencies, while adjusted free cash flow rose by 5% [8] Segment Performance - Health revenues grew by 3% in constant currencies and 4% organically, with Clinical Solutions achieving 5% organic growth [6] - Tax & Accounting revenues increased by 8% in constant currencies and 5% organically, with cloud software subscriptions growing by 19% [7] - Corporate Performance & ESG revenues saw a 10% increase in constant currencies and organically, driven by strong growth in EHS & ESG solutions [11] Cash Flow and Debt - Cash conversion improved modestly, with adjusted free cash flow increasing by 5% in constant currencies [12] - Net debt stood at €3,347 million as of March 31, 2025, with a net-debt-to-EBITDA ratio of 1.7x [13] Shareholder Returns - The company completed €286 million of its planned €1 billion share buyback program as of May 5, 2025 [8][14] - A proposed total dividend of €2.33 for financial year 2024 represents a 12% increase compared to the previous year [15] Guidance and Outlook - Full-year 2025 guidance remains unchanged, with expectations for organic growth in line with prior year [17][21][22] - Adjusted operating profit margin is anticipated to improve, particularly in Health and Corporate Performance & ESG [17]

Core Viewpoint - Vast Resources plc has successfully released a Historic Parcel of diamonds, revealing additional gem-quality stones, which enhances the company's asset value and prepares for future sales [2][3][4]. Company Update - The final packing list has been received following the Kimberly Process inspection, confirming the release of the Historic Parcel [2]. - An Additional Parcel containing 6,055.35 carats of gem-quality stones was discovered, increasing the total estimated quantity of diamonds in the Historic Parcel to 135,139.47 carats, with 36,475.26 carats identified as gem quality [3][4]. - The company is currently sorting the diamonds in Dubai and plans to clean and prepare them for sale, with initial results expected in the coming weeks [4]. Sales Strategy - The Board anticipates a phased selling process to maximize value for the company and its shareholders [4]. - The company looks forward to providing further updates as progress continues [5]. Company Profile - Vast Resources plc is an AIM quoted mining company with operations in Romania, Tajikistan, and Zimbabwe, focusing on advancing high-quality projects and recommencing production at previously operating mines [8]. - The Romanian portfolio includes a 100% interest in the Baita Plai Polymetallic Mine, which has a JORC compliant Reserve & Resource Report supporting an initial production life of approximately 3-4 years [9]. - The company is also working on bringing the Manaila Polymetallic Mine back into production and has secured an Extended Exploitation Licence for further resource examination [10]. - In Tajikistan, Vast has a joint venture for the Takob Mine, providing a 12.25% royalty on sales, and is contracted to manage the Aprelevka gold mines, aiming to increase production to historical peak levels [12][13].